Vivek Subbiah is delighted to host a JAMA Oncology Podcast with the amazing Eileen M. O’Reilly

Vivek Subbiah shared a post on LinkedIn:

”Such a delight to host a JAMA Oncology Podcast with the amazing Dr. Eileen M. O’Reilly, Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center.

We talk about how an AI based classifier reclassified approximately 20% of cases with pancreatic cancer.

Immunotherapy for patients with Lynch syndrome or somatic MSI-H Pancreatic cancer provided significant benefit – AI and precision medicine.

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Genetics and Genomics.

Hosted on American Medical Association Ed Hub.

Link to podcast.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.

Eileen M. O’Reilly is the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center. She leads the Hepatopancreaticobiliary/Neuroendocrine Cancers section and is Co-Director of Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer. She is also an Attending Physician at MSK, a Professor at Weill Cornell Medical College, and Chair of the Human Research Protection Program/IRB. Her work focuses on pancreatic and hepatobiliary malignancies.